J&J’s Acclarent Sees FDA Clearance as It Readies for Acquisition by Integra

Acclarent, a division of Johnson & Johnson, has received FDA clearance for use of its AERA eustachian tube balloon dilation system in the treatment of children age 8-17 with persistent obstructive eustachian tube dysfunction (OETD), the first such treatment available for children.
Source: Drug Industry Daily